PubMed Health⌕ Search

Biomedical subjects

C Albera

Publications and source records attributed to C Albera.

32 records · Page 2Linked to original sources
PubMed1989

Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1.

Lonidamine (LND) interferes with the energy mechanisms of neoplastic cells and decreases the oxygen consumption in human and experimental tumors. The present study was performed in advanced non-small cell lung cancer patients, previously untreated, to confirm the preliminary data of activity against this kind of tumor. LND was given orally in three divided doses increasing to 250 mg/m2 over 4 days. Thirty-six patients were evaluable for toxicity and 33 for response. Partial responses were 3 (9%) and stabilization of disease 15 (45,5%). Recorded side effects (testicular pain, nausea and vomiting, skin hyperesthesia) were mostly mild to moderate with the exclusion of myalgias. Chronic treatment was devoid of haematological, renal, cardiac and pulmonary toxicities. LND as single agent seems to be marginally active in advanced non-small cell lung cancer.

Aged↗
PubMed1989

Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.

Pretreatment serum neuron specific enolase (NSE) and plasma bombesin/gastrin releasing peptide (BN/GRP) were measured in 92 lung cancer patients and 17 controls. The mean level of NSE (p less than 0.001) and BN/GRP (p less than 0.05) was significantly raised in patients with small cell lung cancer (SCLC, n = 62) compared to non-SCLC (n = 30) and controls. The mean concentration of NSE in extensive SCLC was significantly greater (p less than 0.005) than in limited stage but with a substantial overlap of values. Forty-seven out of 62 SCLC patients had at least one of the two markers raised (sensitivity 76%, specificity 83%), 44 had raised NSE (sensitivity 71%, specificity 89%) but only 24 had BN/GRP raised (sensitivity 42%, specificity 91%). At restaging, 16 of 19 patients with SCLC responsive to chemotherapy showed a significant fall of NSE; on the other hand, BN/GRP fell significantly in only 3 patients, remaining unchanged in the majority of responding patients. In conclusion, the combined determination of NSE and BN/GRP in SCLC, at diagnosis and during the follow-up, was not found to be superior to NSE determination alone.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.

Twenty-nine patients with advanced non small cell lung cancer (NSCLC) were treated with a combination of high-dose cisplatin and divided-dose vinblastine. In 27 evaluable patients 15% reached partial response and 59% stable disease. Extension of disease, histological type, performance status and weight loss had no relationship to response. Median duration of response was 10.2 months with a median survival time of 15.4 months in responding patients compared with 14 months of stable disease (p:n.s.) and 4.8 months of progressive disease (p less than 0.001). Gastrointestinal, neurological side effects and the development of a severe debilitation syndrome were the most troublesome toxicities of this treatment. The regimen is not generally suitable for treatment of advanced NSCLC.

Adult↗
PubMed1985

Relationship between circulating immune complexes, serum interferon and clinical features in sarcoidosis.

In order to assess the importance of circulating interferons and immune complexes as hypothetical mediators of some immune derangements observed in sarcoidosis, we evaluated serum interferon and immune complex levels in 45 patients with active disease. In none of our patients could circulating interferon be detected, suggesting that an infectious (viral) etiology is very unlikely, and that a great difference exists between sarcoidosis and true autoimmune diseases. On the other hand, circulating immune complexes could be found in 64.4% of our patients. A good correlation could be found with disease stage and duration, but only with 67Ga lung scan among other activity indexes.

Adult↗
PubMed1985

Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.

69 patients with unresectable non-small cell lung cancer, previously untreated, received cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 4, 6, 8 at 4-week intervals. 66 patients were evaluable for tumor response and toxicity. Overall objective response was 25.7% (3 complete responses and 14 partial responses). Response rate in limited disease was 41% and in patients with performance score 0 it was 40%. Squamous cell carcinoma and adenocarcinoma responded in 31 and 24% of evaluable patients. Complete response was associated with a long duration of remission. Median survival time of responding patients was significantly superior to the median of nonresponding patients (p less than 0.001) but compared to stable disease no statistical significance was demonstrable (p greater than 0.05). Hematological and renal toxicity of proposed regimen was generally mild. Nausea and vomiting were the most noxious side effects.

Aged↗
PubMed1984

[Diagnosis of tuberculosis today].

Authors analyse the main aspects about the diagnosis of tuberculosis and they emphasize that the bacteriological and immunological tests are very important, beside the clinical, radiologic and hematic picture. As regards bacteriological research, Authors dwell upon the significance of repeated sputum specimens and they reevaluate the use of fluorochrome staining. The immunological "in vivo" tests are represented by tuberculin skin test, that must be correctly made and valued to avoid wrong unresponsiveness, at the other hand also caused by host factors. About immunological "in vitro" tests, Authors report the good prospects opened by the serological diagnosis with an immunoenzymatic method specific for S antigen of M. tuberculosis.

Antigens, Bacterial↗
PubMed1980

[Evaluation of leukocyte migration inhibition (LIF) in patients with carcinoma of the lung before and after the use of levamisole in vitro].

Aspecific immunosuppression in neoplasia has long been known, even though all its biological aspects are not yet fully understood. Inhibition of leukocyte migration (LIF) was studied before and after the use of levamisole in vitro to determine whether changes occurred in cell reactivity. The results of the investigation are discussed in the light of modern immunopathological theories.

Humans↗
PubMed1980

[Sarcoidosis].

Explore the source record for details and available documents.

Adrenal Cortex Hormones↗
PubMedDate not supplied

[In vitro lymphocyte immunoreactivity in sarcoidosis patients. Stimulation with Kveim antigens].

12 patients suffering from sarcoidosis have been studied in addition to clinical and bioptic investigations, they were submitted to intradermal reaction with PPD, Candida Albicans and Kveim's antigen. Lymphocytes from the 12 patients were placed in culture and stimulated with phytohaemagglutinin (PHA), pokeweed mitogen (PWM), concanavalin A (CON-A), PPD, Candidin and Kveim's antigen. Six patients proved positive to Kveim's antigen in vivo, and four of them (66%) in vitro also. No patient was immunodepressed. Of the 6 patients negative to Kveim's antigen both in vivo and in vitro, 4 were clearly immunodepressed, as shown by the reduced mitogen response, the negative response to antigen stimulation, and to the intradermal reaction. The results are discussed in the light of recent findings regarding the role of the immunocompetent system in sarcoidosis.

Adult↗